oxender post (13 risultati)

Paperback. Condizione: Wie neu. 2nd printing. XVII, 248 S.; Ill. Like new. Shrink wrapped. Sprache: Englisch Gewicht in Gramm: 510.

gebundene Ausgabe. Condizione: Gut. 248 Seiten Der Erhaltungszustand des hier angebotenen Werks ist trotz seiner Bibliotheksnutzung sehr sauber und kann entsprechende Merkmale aufweisen (Rückenschild, Instituts-Stempel.). In ENGLISCHER Sprache. Sprache: Englisch Gewicht in Gramm: 525.

Condizione: Good. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Clean from markings In good all round condition. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,600grams, ISBN:9783540650256.

Condizione: Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions.

Condizione: Used. pp. 272.

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - A cover story of Business Week Magazine in January 1984 stated 'Biotech Comes of Age'. In February 1986, Venture Magazine had a cover article entitled 'The Biotech Revolution is Here'. This article went on to say 'New Genetic Technologies Will Transform Our Lives'. These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the 'New Biology'. . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the 'high-technology hype', although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, such as peptides, proteins, monoclonal antibodies, nucleic acids and cellular therapies.

Condizione: New. * Study Edition of the successful volume 137 in the Handbook of Experimental Pharmacology series * Original edition already sold outWhile addressing the particular problems associated with several classes of biotechnology products, this book also demons.

Condizione: New. In.

Paperback. Condizione: Brand New. 248 pages. 9.25x6.25x0.50 inches. In Stock.

Hardcover. Condizione: Brand New. 248 pages. 9.75x6.50x0.75 inches. In Stock.

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. * Study Edition of the successful volume 137 in the Handbook of Experimental Pharmacology series * Original edition already sold outWhile addressing the particular problems associated with several classes of biotechnology products, this book also demons.

Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -A cover story of Business Week Magazine in January 1984 stated 'Biotech Comes of Age'. In February 1986, Venture Magazine had a cover article entitled 'The Biotech Revolution is Here'. This article went on to say 'New Genetic Technologies Will Transform Our Lives'. These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the 'New Biology'. . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the 'high-technology hype', although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, such as peptides, proteins, monoclonal antibodies, nucleic acids and cellular therapies.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 272 pp. Englisch.

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -While addressing the particular problems associated with several classes of biotechnology products, this book also demonstrates that the principles are the same as in the development of small new chemical entities. It begins by studying FDA regulatory expectations for biotech products, before moving on to discuss general issues common to each class of biotech drug, such as proteins, peptides, and nucleic acids. The text deals with specific biotech drugs that have successfully made it into clinical trials, and each review is written by a renowned expert in the relevant fields. 272 pp. Englisch.